OXB vs. ONT, ERGO, SLN, PRTC, HZD, FARN, VRP, ARIX, CIR, and BVXP
Should you be buying Oxford Biomedica stock or one of its competitors? The main competitors of Oxford Biomedica include Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.
Oxford Biomedica vs. Its Competitors
Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Oxford Nanopore Technologies has a net margin of -94.82% compared to Oxford Biomedica's net margin of -145.98%. Oxford Nanopore Technologies' return on equity of -26.02% beat Oxford Biomedica's return on equity.
In the previous week, Oxford Nanopore Technologies had 20 more articles in the media than Oxford Biomedica. MarketBeat recorded 20 mentions for Oxford Nanopore Technologies and 0 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 0.29 beat Oxford Biomedica's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.
Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.
Oxford Nanopore Technologies presently has a consensus target price of GBX 220, suggesting a potential upside of 6.19%. Oxford Biomedica has a consensus target price of GBX 390, suggesting a potential upside of 1.83%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.
Oxford Nanopore Technologies has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
38.4% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 64.1% of Oxford Biomedica shares are held by institutional investors. 32.6% of Oxford Nanopore Technologies shares are held by insiders. Comparatively, 21.2% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Oxford Nanopore Technologies beats Oxford Biomedica on 11 of the 16 factors compared between the two stocks.
Get Oxford Biomedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford Biomedica Competitors List
Related Companies and Tools
This page (LON:OXB) was last updated on 7/26/2025 by MarketBeat.com Staff
Free OXB Stock Alerts